Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout

 
• By Alaric DeArment
  
Horizon announced successful results from its Phase II study of dazodalibep in Sjögren's syndrome • Source: Shutterstock

More from Clinical Trials

More from R&D